MISSISSAUGA, ON, Aug. 21 /CNW/ – A new national survey shows that the majority of Canadians at risk for a severe, potentially fatal allergic reaction do not carry their life-saving medication with them. Worse yet, most Canadians would not know what to do in the event of someone having a
potentially fatal allergic attack, known as anaphylaxis.
The new survey of 1,502 Canadians commissioned by King Pharmaceuticals, in collaboration with Anaphylaxis Canada, reveals that only one in five Canadians at risk for an anaphylactic attack remember to carry an epinephrine auto-injector with them at all times. An injection of epinephrine is the definitive treatment for someone experiencing an anaphylactic attack, which can be fatal in minutes if untreated. Additionally, while 97 percent of Canadians are aware that an allergic reaction can kill someone, only 45 percent would know how to treat someone having an allergic reaction by administering a life-saving dose of epinephrine using an emergency auto-injector such as the EpiPen(R) auto-injector (epinephrine injection).
“The results of this survey emphasize the need to educate Canadians about life-threatening allergies and how we can all work together as a community to protect the safety of people who are at risk,” says Laurie Harada, Executive Director, Anaphylaxis Canada. “Since it is often difficult for people to avoid exposure to different allergens, it is important to make sure that an allergic person’s family, friends, and teachers are educated about their allergies. These people should be ready to assist in the event of an emergency.” Approximately 600,000 Canadians (or 1 percent to 2 percent) are estimated to have allergic sensitivities, placing them at risk for anaphylaxis, although some experts believe that this incidence rate could be understated.
The most common triggers for anaphylaxis include foods, insect stings, drugs, latex and exercise. People experiencing anaphylaxis should use an epinephrine auto-injector at the earliest signs of reaction and then call 911 or be taken to an emergency room. According to the study, 35 percent of respondents say they or someone they know has suffered from an anaphylactic reaction.
“If untreated, anaphylaxis can be fatal within minutes, therefore it is vital that individuals with severe allergies carry an up-to-date epinephrine auto-injector at all times,” says Dr. Rhoda Kagan, Pediatric Allergist, North York General Hospital. “In a critical situation where someone is experiencing an anaphylactic reaction, simplicity matters and EpiPen auto-injectors are designed for easy self administration. When administered at the first signs of anaphylaxis, EpiPen auto-injectors can provide individuals the time necessary to obtain more definitive emergency treatment.”
Addtional Survey Highlights
- 75 percent of Canadians think peanuts can cause a more serious allergic reaction than milk, when in fact they both can cause a serious reaction.
- 60 percent of Canadians support a peanut ban in schools and child care centres, but only 27 percent support a peanut ban in all public places.
- Peanut allergy is the most common cause of death from food allergy, in addition to shellfish, fish and tree nuts.
- Half of Canadians think the food industry is doing a good job of declaring dangerous allergens on package label.
- Half of Canadians agree that child care centres should be held responsible if they don’t carry an epinephrine auto-injector and a child on their premises has a severe allergic reaction.
- One in four survey respondents think public places should be held responsible if they don’t carry EpiPen and someone on their premises has a severe allergic reaction.
- 7 out of 10 Canadians agree that restaurants and cafeterias should be required to list all ingredients on their menu products, even if it costs diners more.
About EpiPen
EpiPen (epinephrine) Auto-Injector 0.3/0.15 mg is indicated for emergency treatment of allergic reactions (anaphylaxis). Such emergencies may occur spontaneously or from insect stings, bites, foods, drugs, or other allergens, as well as idiopathic or exercise induced anaphylaxis. How Supplied: EpiPen and EpiPen Jr. auto-injectors are available in single cartons. Further information can be found at www.epipen.ca.
EpiPen should be used with extreme caution in people who have heart disease. Side effects of EpiPen may include fast or irregular heartbeat, nausea, and breathing difficulty. Certain side effects may be increased if EpiPen is used while taking tricyclic antidepressants or monoamine oxidase inhibitors. The EpiPen and EpiPen Jr. are designed as emergency supportive therapy only and are not a replacement or substitute for immediate medical or hospital care.
About King Pharmaceuticals
King, with offices in Mississauga, Ontario and headquartered in Bristol, Tennessee, is a vertically integrated branded pharmaceutical company. King, an S&P 500 Index company, seeks to capitalize on opportunities in the pharmaceutical industry through the development, including through in licensing arrangements and acquisitions, of novel branded prescription pharmaceutical products in attractive markets and the strategic acquisition of branded products that can benefit from focused promotion and marketing and product life-cycle management.
About Anaphylaxis Canada
Anaphylaxis Canada is a non-profit organization created by and for people with anaphylaxis. Anaphylaxis Canada’s mission is to inform, support, educate, and advocate for the needs of individuals and families living with anaphylaxis and to conduct and support research related to anaphylaxis.
About the Survey
The Leger study was commissioned by King Pharmaceuticals, maker of EpiPen (epinephrine autoinjector), and in collaboration with Anaphylaxis Canada. Data collection for this study was conducted via Leger Marketing OmniCan. Data was collected between May 29 and June 3, 2007. A random household selection was achieved by inviting residents across Canada over 18 years of age to complete the survey. A total of 1,502 interviews were completed. The margin of error for a sample of this size is +/- 2.5%, 19 times out of 20.
Note to Photo Editors
A photo accompanying this release is available on the CNW Photo Network and archived at http://photos.newswire.ca. Additional archived images are also available on the CNW Photo Archive website at http://photos.newswire.ca. Images are free to accredited members of the media/
For further information
Media requiring further information, high resolution product images or interviews, please contact:
Saskia Brussaard, Katarina Markovinovic, Porter Novelli
(416) 422-7176, (416) 422-7187, saskia.brussaard@porternovelli.com, katarina.markovinovic@porternovelli.com
In Western Canada: Julie Coghlan
(604) 602-6401, julie.coghlan@porternovelli.com